Compass Pathways just launched "Change the Tune in TRD," an educational campaign helping clinicians better recognize and manage treatment-resistant depression (TRD). The initiative challenges the widespread acceptance of partial improvement as the best possible outcome, pushing instead for full remission as the goal. It's aimed at all U.S. HCPs treating depression — including primary care providers.
Compass Pathways, a biotech company focused on mental health innovation, has launched Change the Tune in TRD — a U.S.-based educational campaign designed to shift how healthcare professionals think about and manage treatment-resistant depression (TRD). The initiative targets any clinician treating depression, with a particular emphasis on primary care, where most depression is managed.
The campaign challenges a troubling status quo: both patients and providers have come to accept partial symptom relief as "good enough." Interventional psychiatrist Dr. Sandhya Prashad argues that remission — not just improvement — should be the standard, and that it's achievable for many TRD patients. The program also highlights the role of brain network connectivity in TRD, offering clinicians a clearer framework for understanding why standard treatments sometimes fall short.
Key Takeaways:
Why it matters: TRD carries enormous personal and societal burden, yet it's frequently undertreated due to low expectations. By reframing TRD as "treatment hasn't succeeded yet" rather than "the patient is failing," this campaign could meaningfully raise the standard of care and restore hope for millions of patients.
